INC Research Holdings (NASDAQ: INCR) recently received a number of ratings updates from brokerages and research firms:

  • 10/11/2017 – INC Research Holdings is now covered by analysts at Credit Suisse Group. They set an “outperform” rating and a $68.00 price target on the stock.
  • 10/9/2017 – INC Research Holdings had its “buy” rating reaffirmed by analysts at Robert W. Baird. They now have a $67.00 price target on the stock.
  • 10/9/2017 – INC Research Holdings was upgraded by analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating. They now have a $69.00 price target on the stock, up previously from $62.50.
  • 10/4/2017 – INC Research Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
  • 9/27/2017 – INC Research Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $58.00 price target on the stock. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
  • 9/21/2017 – INC Research Holdings is now covered by analysts at Mizuho. They set a “neutral” rating and a $57.00 price target on the stock.

INC Research Holdings, Inc. (INCR) opened at 55.25 on Wednesday. INC Research Holdings, Inc. has a one year low of $40.65 and a one year high of $61.10. The stock’s 50 day moving average is $54.21 and its 200 day moving average is $54.29. The firm has a market capitalization of $2.99 billion, a P/E ratio of 33.85 and a beta of 1.34.

INC Research Holdings (NASDAQ:INCR) last issued its earnings results on Thursday, July 27th. The company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. The company had revenue of $258.10 million for the quarter, compared to analysts’ expectations of $256.76 million. INC Research Holdings had a net margin of 5.69% and a return on equity of 40.69%. The firm’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company earned $0.61 EPS. On average, equities research analysts predict that INC Research Holdings, Inc. will post $2.59 earnings per share for the current fiscal year.

In related news, CFO Gregory S. Rush sold 88,739 shares of INC Research Holdings stock in a transaction on Friday, September 1st. The shares were sold at an average price of $58.99, for a total value of $5,234,713.61. Following the transaction, the chief financial officer now owns 149,301 shares in the company, valued at approximately $8,807,265.99. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Gregory S. Rush sold 9,703 shares of INC Research Holdings stock in a transaction on Monday, September 18th. The stock was sold at an average price of $54.48, for a total transaction of $528,619.44. Following the completion of the transaction, the chief financial officer now owns 78,593 shares in the company, valued at approximately $4,281,746.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 198,321 shares of company stock worth $11,550,792. 0.24% of the stock is owned by corporate insiders.

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Receive News & Ratings for INC Research Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.